Citi analyst Yigal Nochomovitz lowered the firm’s price target on Syndax to $30 from $32 and keeps a Buy rating on the shares following the Q1 report. The company in the second half of 2024 could achieve two major milestones with the potential approvals of both axatilimab and revumenib, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
- Syndax price target lowered to $32 from $35 at Citi
- Syndax management to meet with BTIG
- Syndax presents ‘positive’ results from AUGMENT-101 trial of Revumenib
- Syndax completes enrollment in AUGMENT-101 trial